The first study [15] focused on 309 late-middle-aged adults (mean age 61 years) and found KL-VSHET+ to be associated with reduced Aβ aggregation, suggesting its protective effect against APOE ε4-linked pathways to disease onset in AD. This evidence concerns the gene APOE and Alzheimer disease.